Sonnessa Margherita, Sergio Sara, Saponaro Concetta, Maffia Michele, Vergara Daniele, Zito Francesco Alfredo, Tinelli Andrea
Functional Biomorphology Laboratory, Pathology Department, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Lecce, Italy.
Front Oncol. 2022 Feb 11;12:836630. doi: 10.3389/fonc.2022.836630. eCollection 2022.
Gynecological cancer management remains challenging and a better understanding of molecular mechanisms that lead to carcinogenesis and development of these diseases is needed to improve the therapeutic approaches. The Na/H exchanger regulatory factor 1 (NHERF1) is a scaffold protein that contains modular protein-interaction domains able to interact with molecules with an impact on carcinogenesis and cancer progression. During recent years, its involvement in gynecological cancers has been explored, suggesting that NHERF1 could be a potential biomarker for the development of new targeted therapies suitable to the management of these tumors. This comprehensive review provides an update on the recent study on NHERF1 activity and its pathological role in cervical and ovarian cancer, as well as on its probable involvement in the therapeutic landscape of these cancer types.
妇科癌症的管理仍然具有挑战性，需要更好地了解导致这些疾病发生和发展的分子机制，以改进治疗方法。钠/氢交换调节因子1（NHERF1）是一种支架蛋白，它包含模块化的蛋白质相互作用结构域，能够与对癌症发生和癌症进展有影响的分子相互作用。近年来，人们对其在妇科癌症中的作用进行了探索，这表明NHERF1可能是开发适用于这些肿瘤管理的新型靶向治疗药物的潜在生物标志物。这篇综述全面介绍了NHERF1活性及其在宫颈癌和卵巢癌中的病理作用的最新研究，以及它可能在这些癌症类型治疗中的作用。
